<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01831661</url>
  </required_header>
  <id_info>
    <org_study_id>10-VIN-183</org_study_id>
    <nct_id>NCT01831661</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting Condition</brief_title>
  <official_title>A Randomized, Open Label, Two-treatment, Two -Period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India and GLUCOPHAGE®XR (Metformin HCl Extended-release Tablets) 750 mg of Bristol-Myers Squibb Company, USA in Normal, Healthy, Adult, Human Subjects Under Fasting Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IPCA Laboratories Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IPCA Laboratories Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was a randomized, open label, two-treatment, two-period, two-sequence, single dose,&#xD;
      crossover, oral bioequivalence study in normal, healthy adult human subjects under fasting&#xD;
      condition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective of the study is to compare and evaluate the single-dose oral bioavailability of&#xD;
      Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India&#xD;
      and GLUCOPHAGE®XR (Metformin HCl extended-release tablets) 750 mg of Bristol-Myers Squibb&#xD;
      Company, USA in normal, healthy, adult, human subjects under fasting condition.&#xD;
&#xD;
      Total duration of the study was of 17 days from the day of admission of first period till the&#xD;
      end of second period.&#xD;
&#xD;
      Upon entering into the study, subjects were housed in clinical facility of Veeda Clinical&#xD;
      Research Pvt. Ltd. to ensure 10 hours overnight fasting before dosing and continued to be&#xD;
      housed in the facility till 36.00 hours post-dose blood sample collection in each of the two&#xD;
      periods.&#xD;
&#xD;
      A gap of 14 days was kept as wash out between each consecutive dosing period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence is based on Cmax and AUC parameters.</measure>
    <time_frame>1 Months</time_frame>
    <description>Pre-dose &amp; at 1.00, 2.00, 3.00, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 8.00, 9.00, 10.00, 12.00, 16.00, 20.00, 24.00, 30.00 and 36.00 hours post-dose.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Fasting</condition>
  <arm_group>
    <arm_group_label>GLUCOPHAGE®XR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GLUCOPHAGE®XR (Metformin HCl extended-release tablets) 750 mg of Bristol-Myers Squibb Company, USA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin Hydrochloride Extended-Release Tablets USP 750 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride Extended-Release Tablets USP 750 mg</intervention_name>
    <description>Metformin Hydrochloride Extended-Release Tablets 750 mg once a day</description>
    <arm_group_label>GLUCOPHAGE®XR</arm_group_label>
    <arm_group_label>Metformin Hydrochloride Extended-Release Tablets USP 750 mg</arm_group_label>
    <other_name>Test Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLUCOPHAGE®XR</intervention_name>
    <description>GLUCOPHAGE®XR 750 mg once a day</description>
    <arm_group_label>GLUCOPHAGE®XR</arm_group_label>
    <arm_group_label>Metformin Hydrochloride Extended-Release Tablets USP 750 mg</arm_group_label>
    <other_name>Reference product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects aged between 18 and 45 years (including both).&#xD;
&#xD;
          2. Subjects' weight within normal range according to normal values for Body Mass Index&#xD;
             (18.5 to 24.9 kg/m2) (including both) with minimum of 50 kg weight.&#xD;
&#xD;
          3. Subjects with normal health as determined by personal medical history, clinical&#xD;
             examination and laboratory examinations within clinically acceptable normal range.&#xD;
&#xD;
          4. Subjects having clinically acceptable 12-lead electrocardiogram (ECG).&#xD;
&#xD;
          5. Subjects having clinically acceptable chest X-Ray (PA view).&#xD;
&#xD;
          6. Subjects having negative urine screen for drugs of abuse (including amphetamines,&#xD;
             barbiturates, benzodiazepines, marijuana, cocaine, and morphine).&#xD;
&#xD;
          7. Subjects having negative alcohol breathe test.&#xD;
&#xD;
          8. Subjects willing to adhere to protocol requirements and to provide written informed&#xD;
             consent.&#xD;
&#xD;
          9. Subjects having negative Beta-hCG Pregnancy test (only for female subjects).&#xD;
&#xD;
         10. For Female Subjects:&#xD;
&#xD;
        1) Female of child bearing potential practicing an acceptable method of birth control for&#xD;
        the duration of the study as judged by the investigator(s), such as condoms, foams,&#xD;
        jellies, diaphragm, intrauterine device (IUD), or abstinence, or 2) Postmenopausal for at&#xD;
        least 1 year, or if less than 1 year, then following acceptable contraceptive measures as&#xD;
        mentioned above 3) Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
        hysterectomy has been performed on the subject).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to Metformin or to any excipients or related class of drugs.&#xD;
&#xD;
          2. History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             gastrointestinal, endocrine, immunological, dermatological, neurological or&#xD;
             psychiatric disease or disorder.&#xD;
&#xD;
          3. Any treatment which could bring about induction or inhibition of hepatic microsomal&#xD;
             enzyme system within 1 month of the study starting&#xD;
&#xD;
          4. History or Presence of significant alcoholism or drug abuse.&#xD;
&#xD;
          5. History or presence of significant asthma, urticaria or other allergic reactions.&#xD;
&#xD;
          6. History or presence of significant gastric and/or duodenal ulceration.&#xD;
&#xD;
          7. History or presence of significant thyroid disease, adrenal dysfunction, organic&#xD;
             intracranial lesion such as pituitary tumor.&#xD;
&#xD;
          8. History or presence of cancer.&#xD;
&#xD;
          9. History or presence of significant easy bruising or bleeding.&#xD;
&#xD;
         10. History or presence of significant recent trauma.&#xD;
&#xD;
         11. Subjects who have been on an abnormal diet (for whatever reason) during four weeks&#xD;
             preceding the study.&#xD;
&#xD;
         12. Difficulty with donating blood.&#xD;
&#xD;
         13. Difficulty in swallowing solids like tablets or capsules.&#xD;
&#xD;
         14. Use of any prescribed or OTC medication during last two weeks prior to dosing in&#xD;
             period 01.&#xD;
&#xD;
         15. Consumption of grapefruit juice, xanthine-containing products, tobacco containing&#xD;
             products or alcohol within 48 hours prior to dosing.&#xD;
&#xD;
         16. Major illness during 3 months before screening.&#xD;
&#xD;
         17. Participation in a drug research study within past 3 months.&#xD;
&#xD;
         18. Donation of blood from past 3 months before screening.&#xD;
&#xD;
         19. Female subjects who are currently breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Hardik Dave, M.B.B.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veeda Clinical Research Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veeda Clinical Research Pvt. Ltd.</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 6, 2013</study_first_submitted>
  <study_first_submitted_qc>April 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

